Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics

被引：0
|
作者：
Nael Al Koudsi
Jill C. Mwenifumbo
Edward M. Sellers
Neal L. Benowitz
Gary E. Swan
Rachel F. Tyndale
机构：
[1] University of Toronto,Centre for Addiction & Mental Health, and Department of Pharmacology
[2] University of California,Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, and Departments of Medicine, Psychiatry and Biopharmaceutical Sciences
[3] SRI International,Center for Health Sciences
[4] University of Toronto,undefined
来源：
European Journal of Clinical Pharmacology | 2006年 / 62卷
关键词：
CYP2A6; Nicotine metabolism; Polymorphism; Pharmacogenetics; Smoking;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：481 / 484
页数：3
相关论文
共 50 条
  • [41] Whole deletion of CYP2A6 gene (CYP2A6*4C) and smoking behavior
    Iwahashi, K
    Waga, C
    Takimoto, T
    NEUROPSYCHOBIOLOGY, 2004, 49 (02) : 101 - 104
  • [42] Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review
    Jones, Stephanie K.
    Wolf, Bethany J.
    Froeliger, Brett
    Wallace, Kristin
    Carpenter, Matthew J.
    Alberg, Anthony J.
    NICOTINE & TOBACCO RESEARCH, 2022, 24 (05) : 633 - 642
  • [43] Relationship between CYP2A6 Genetic Polymorphism, as a Marker of Nicotine Metabolism, and Ulcerative Colitis
    Altarescu, Gheona
    Rachmilewitz, Daniel
    Zevin, Shoshana
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2011, 13 (02): : 87 - 90
  • [44] CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people
    Binnington, Matthew J.
    Zhu, Andy Z. X.
    Renner, Caroline C.
    Lanier, Anne P.
    Hatsukami, Dorothy K.
    Benowitz, Neal L.
    Tyndale, Rachel F.
    PHARMACOGENETICS AND GENOMICS, 2012, 22 (06) : 429 - 440
  • [45] SNPs within CHRNA5-A3-B4 and CYP2A6/B6, nicotine metabolite concentrations and nicotine dependence treatment success in smokers
    Hubacek, Jaroslav A.
    Kurcova, Ivana
    Maresova, Vera
    Pankova, Alexandra
    Stepankova, Lenka
    Zvolska, Kamila
    Lanska, Vera
    Kralikova, Eva
    BIOMEDICAL PAPERS-OLOMOUC, 2021, 165 (01): : 84 - 89
  • [46] Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors
    Nael Al Koudsi
    Ewa B. Hoffmann
    Abbas Assadzadeh
    Rachel F. Tyndale
    European Journal of Clinical Pharmacology, 2010, 66 : 239 - 251
  • [47] Novel human CYP2A6 alleles confound gene deletion analysis
    Nakajima, M
    Yoshida, R
    Fukami, T
    McLeod, HL
    Yokoi, T
    FEBS LETTERS, 2004, 569 (1-3): : 75 - 81
  • [48] CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians
    Inoue, K
    Yamazaki, H
    Shimada, T
    ARCHIVES OF TOXICOLOGY, 2000, 73 (10-11) : 532 - 539
  • [49] The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans
    Bloom, Joseph
    Hinrichs, Anthony L.
    Wang, Jen C.
    von Weymarn, Linda B.
    Kharasch, Evan D.
    Bierut, Laura J.
    Goate, Alison
    Murphy, Sharon E.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (07) : 403 - 416
  • [50] An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles
    Xu, C
    Rao, YS
    Xu, B
    Hoffmann, E
    Jones, J
    Sellers, EM
    Tyndale, RF
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (01) : 318 - 324
12345